[{"address1": "Shengda Science Park", "address2": "Building A, Floor 18 No.19 Jugong Road Binjiang District", "city": "Hangzhou", "zip": "310051", "country": "China", "phone": "86 571 2888 7227", "fax": "86 571 8821 1196", "website": "https://www.tigermedgrp.com", "industry": "Diagnostics & Research", "sector": "Healthcare", "longBusinessSummary": "Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides product market research, product marketing strategy, product finalization, product verification, registration strategy planning, marketing application, post-marketing supports, and product upgrade services. In addition, the company offers medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional services, EDC system, and call center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.", "fullTimeEmployees": 9348, "companyOfficers": [{"maxAge": 1, "name": "Dr. Xiaoping  Ye D.Phil, EMBA, M.D., Ph.D.", "age": 60, "title": "Co-Founder & Chairman", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xiaochun  Cao M.D.", "age": 54, "title": "Co-Founder, GM & Executive Director", "yearBorn": 1969, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hao  Wu", "age": 56, "title": "President & Executive Director", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Chengcheng  Yang", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zengyu  Wen", "age": 43, "title": "Executive VP, COO & Executive Director", "yearBorn": 1980, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiao Ri  Li", "age": 40, "title": "Secretary", "yearBorn": 1983, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tianrong  Ji M.D., Ph.D.", "title": "Chief Investment Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guoyun  Yu", "title": "Head of Accounting Department", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jiansong  Yang Ph.D.", "title": "Senior VP & Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alan  Liu", "title": "Chief Compliance Officer", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "open": 4.28, "dayLow": 4.2, "dayHigh": 4.28, "regularMarketOpen": 4.28, "regularMarketDayLow": 4.2, "regularMarketDayHigh": 4.28, "dividendRate": 0.08, "dividendYield": 0.0187, "exDividendDate": 1718064000, "payoutRatio": 0.21149999, "beta": 0.735, "trailingPE": 11.351351, "volume": 612, "regularMarketVolume": 612, "marketCap": 5922882048, "fiftyTwoWeekLow": 4.2, "fiftyTwoWeekHigh": 7.78, "priceToSalesTrailing12Months": 0.8423435, "fiftyDayAverage": 4.2, "twoHundredDayAverage": 4.4337, "trailingAnnualDividendRate": 0.568, "trailingAnnualDividendYield": "Infinity", "currency": "USD", "enterpriseValue": 7774919168, "profitMargins": 0.16062, "floatShares": 622302625, "sharesOutstanding": 123125000, "bookValue": 24.104, "priceToBook": 0.17424493, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.686, "netIncomeToCommon": 1129361792, "trailingEps": 0.37, "enterpriseToRevenue": 1.106, "enterpriseToEbitda": 4.594, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "HNGZY", "underlyingSymbol": "HNGZY", "shortName": "HANGZHOU TIGERMED CONSULTING CO", "longName": "Hangzhou Tigermed Consulting Co., Ltd", "firstTradeDateEpochUtc": 1657546200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6dd3f5bd-6601-3de3-81d2-80ead818383b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.2, "recommendationKey": "none", "totalCash": 3215138304, "totalCashPerShare": 3.732, "ebitda": 1692304640, "totalDebt": 4069460224, "quickRatio": 1.408, "currentRatio": 1.434, "totalRevenue": 7031433216, "debtToEquity": 16.909, "revenuePerShare": 8.118, "returnOnAssets": 0.031070001, "returnOnEquity": 0.054109998, "freeCashflow": 98204032, "operatingCashflow": 952725056, "earningsGrowth": -0.684, "revenueGrowth": -0.109, "grossMargins": 0.38361, "ebitdaMargins": 0.24068001, "operatingMargins": 0.20395, "financialCurrency": "CNY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]